secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2025-09-02T23:59:59+00:00
Accession:  0001650664-25-000134
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas Medicine nominates EDIT-401 as lead in vivo candidate; ~90% LDL-C reduction in NHPs
--------------------------------------------------------------------------------

- EDIT-401 achieved ~90% mean LDL-C reduction after single dose in non-human primates across all doses (1.5-4 mg/kg), sustained for one month.
- Observed at least 6-fold mean increase in LDLR protein levels; no adverse effects; transient liver enzyme increases resolved within one week.
- Plans to submit IND/CTA for EDIT-401 by mid-2026 with human proof-of-concept data targeted by end of 2026.
- Company re-confirmed cash runway into Q2 2027 based on existing cash and Vertex payments.
- Editas will focus resources on EDIT-401 advancement; intends to identify additional target cell type by end of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066425000134/0001650664-25-000134-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066425000134/edit-20250902.htm
  HTML page:      https://secwatch.observer/filing/0001650664-25-000134

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer